Mylan Launches Generic Version of Wellbutrin XL(R) Tablets

Emirates PharmaAdvertisement

Mylan Pharmaceuticals Inc. has launched Bupropion Hydrochloride Extended-release Tablets USP, (XL), 150 mg and 300 mg (Once-Daily), the generic version of GlaxoSmithKline’s antidepressant Wellbutrin XL(R). Bupropion Hydrochloride Extended-release Tablets had U.S. sales of approximately $752 million for the 12 months ending June 30, 2010, according to IMS Health.

Currently, Mylan has 150 ANDAs pending FDA approval representing $94.2 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $21.9 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Emirates PharmaAdvertisement